img

Global Infliximab and Biosimilar Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Infliximab and Biosimilar Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Infliximab and Biosimilar market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Infliximab and Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Infliximab and Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Infliximab and Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Infliximab and Biosimilar include Janssen Biotech, Merck and Co. and Pfizer, etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Infliximab and Biosimilar, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Infliximab and Biosimilar by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Infliximab and Biosimilar market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Infliximab and Biosimilar market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Janssen Biotech
Merck and Co.
Pfizer
By Type
Infliximab
Infliximab-dyyb
Infliximab-abda
By Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Infliximab and Biosimilar in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Infliximab and Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Infliximab and Biosimilar sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Infliximab and Biosimilar Definition
1.2 Market by Type
1.2.1 Global Infliximab and Biosimilar Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Infliximab
1.2.3 Infliximab-dyyb
1.2.4 Infliximab-abda
1.3 Market Segment by Application
1.3.1 Global Infliximab and Biosimilar Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Crohn's Disease
1.3.3 Pediatric Crohn's Disease
1.3.4 Ulcerative Colitis
1.3.5 Rheumatoid Arthritis
1.3.6 Ankylosing Spondylitis
1.3.7 Psoriatic Arthritis
1.3.8 Plaque Psoriasis
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Infliximab and Biosimilar Sales
2.1 Global Infliximab and Biosimilar Revenue Estimates and Forecasts 2018-2034
2.2 Global Infliximab and Biosimilar Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Infliximab and Biosimilar Revenue by Region
2.3.1 Global Infliximab and Biosimilar Revenue by Region (2018-2023)
2.3.2 Global Infliximab and Biosimilar Revenue by Region (2024-2034)
2.4 Global Infliximab and Biosimilar Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Infliximab and Biosimilar Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Infliximab and Biosimilar Sales Quantity by Region
2.6.1 Global Infliximab and Biosimilar Sales Quantity by Region (2018-2023)
2.6.2 Global Infliximab and Biosimilar Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Infliximab and Biosimilar Sales Quantity by Manufacturers
3.1.1 Global Infliximab and Biosimilar Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Infliximab and Biosimilar Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Infliximab and Biosimilar Sales in 2024
3.2 Global Infliximab and Biosimilar Revenue by Manufacturers
3.2.1 Global Infliximab and Biosimilar Revenue by Manufacturers (2018-2023)
3.2.2 Global Infliximab and Biosimilar Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Infliximab and Biosimilar Revenue in 2024
3.3 Global Infliximab and Biosimilar Sales Price by Manufacturers
3.4 Global Key Players of Infliximab and Biosimilar, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Infliximab and Biosimilar, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Infliximab and Biosimilar, Product Offered and Application
3.8 Global Key Manufacturers of Infliximab and Biosimilar, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Infliximab and Biosimilar Sales Quantity by Type
4.1.1 Global Infliximab and Biosimilar Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Infliximab and Biosimilar Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Infliximab and Biosimilar Sales Quantity Market Share by Type (2018-2034)
4.2 Global Infliximab and Biosimilar Revenue by Type
4.2.1 Global Infliximab and Biosimilar Historical Revenue by Type (2018-2023)
4.2.2 Global Infliximab and Biosimilar Forecasted Revenue by Type (2024-2034)
4.2.3 Global Infliximab and Biosimilar Revenue Market Share by Type (2018-2034)
4.3 Global Infliximab and Biosimilar Price by Type
4.3.1 Global Infliximab and Biosimilar Price by Type (2018-2023)
4.3.2 Global Infliximab and Biosimilar Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Infliximab and Biosimilar Sales Quantity by Application
5.1.1 Global Infliximab and Biosimilar Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Infliximab and Biosimilar Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Infliximab and Biosimilar Sales Quantity Market Share by Application (2018-2034)
5.2 Global Infliximab and Biosimilar Revenue by Application
5.2.1 Global Infliximab and Biosimilar Historical Revenue by Application (2018-2023)
5.2.2 Global Infliximab and Biosimilar Forecasted Revenue by Application (2024-2034)
5.2.3 Global Infliximab and Biosimilar Revenue Market Share by Application (2018-2034)
5.3 Global Infliximab and Biosimilar Price by Application
5.3.1 Global Infliximab and Biosimilar Price by Application (2018-2023)
5.3.2 Global Infliximab and Biosimilar Price Forecast by Application (2024-2034)
6 North America
6.1 North America Infliximab and Biosimilar Sales by Company
6.1.1 North America Infliximab and Biosimilar Revenue by Company (2018-2023)
6.1.2 North America Infliximab and Biosimilar Sales Quantity by Company (2018-2023)
6.2 North America Infliximab and Biosimilar Market Size by Type
6.2.1 North America Infliximab and Biosimilar Sales Quantity by Type (2018-2034)
6.2.2 North America Infliximab and Biosimilar Revenue by Type (2018-2034)
6.3 North America Infliximab and Biosimilar Market Size by Application
6.3.1 North America Infliximab and Biosimilar Sales Quantity by Application (2018-2034)
6.3.2 North America Infliximab and Biosimilar Revenue by Application (2018-2034)
6.4 North America Infliximab and Biosimilar Market Size by Country
6.4.1 North America Infliximab and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Infliximab and Biosimilar Revenue by Country (2018-2034)
6.4.3 North America Infliximab and Biosimilar Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Infliximab and Biosimilar Sales by Company
7.1.1 Europe Infliximab and Biosimilar Sales Quantity by Company (2018-2023)
7.1.2 Europe Infliximab and Biosimilar Revenue by Company (2018-2023)
7.2 Europe Infliximab and Biosimilar Market Size by Type
7.2.1 Europe Infliximab and Biosimilar Sales Quantity by Type (2018-2034)
7.2.2 Europe Infliximab and Biosimilar Revenue by Type (2018-2034)
7.3 Europe Infliximab and Biosimilar Market Size by Application
7.3.1 Europe Infliximab and Biosimilar Sales Quantity by Application (2018-2034)
7.3.2 Europe Infliximab and Biosimilar Revenue by Application (2018-2034)
7.4 Europe Infliximab and Biosimilar Market Size by Country
7.4.1 Europe Infliximab and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Infliximab and Biosimilar Revenue by Country (2018-2034)
7.4.3 Europe Infliximab and Biosimilar Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Infliximab and Biosimilar Sales by Company
8.1.1 China Infliximab and Biosimilar Sales Quantity by Company (2018-2023)
8.1.2 China Infliximab and Biosimilar Revenue by Company (2018-2023)
8.2 China Infliximab and Biosimilar Market Size by Type
8.2.1 China Infliximab and Biosimilar Sales Quantity by Type (2018-2034)
8.2.2 China Infliximab and Biosimilar Revenue by Type (2018-2034)
8.3 China Infliximab and Biosimilar Market Size by Application
8.3.1 China Infliximab and Biosimilar Sales Quantity by Application (2018-2034)
8.3.2 China Infliximab and Biosimilar Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Infliximab and Biosimilar Sales by Company
9.1.1 APAC Infliximab and Biosimilar Sales Quantity by Company (2018-2023)
9.1.2 APAC Infliximab and Biosimilar Revenue by Company (2018-2023)
9.2 APAC Infliximab and Biosimilar Market Size by Type
9.2.1 APAC Infliximab and Biosimilar Sales Quantity by Type (2018-2034)
9.2.2 APAC Infliximab and Biosimilar Revenue by Type (2018-2034)
9.3 APAC Infliximab and Biosimilar Market Size by Application
9.3.1 APAC Infliximab and Biosimilar Sales Quantity by Application (2018-2034)
9.3.2 APAC Infliximab and Biosimilar Revenue by Application (2018-2034)
9.4 APAC Infliximab and Biosimilar Market Size by Region
9.4.1 APAC Infliximab and Biosimilar Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Infliximab and Biosimilar Revenue by Region (2018-2034)
9.4.3 APAC Infliximab and Biosimilar Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Infliximab and Biosimilar Sales by Company
10.1.1 Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Infliximab and Biosimilar Market Size by Type
10.2.1 Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Infliximab and Biosimilar Market Size by Application
10.3.1 Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Infliximab and Biosimilar Market Size by Country
10.4.1 Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Janssen Biotech
11.1.1 Janssen Biotech Company Information
11.1.2 Janssen Biotech Overview
11.1.3 Janssen Biotech Infliximab and Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Janssen Biotech Infliximab and Biosimilar Products and Services
11.1.5 Janssen Biotech Infliximab and Biosimilar SWOT Analysis
11.1.6 Janssen Biotech Recent Developments
11.2 Merck and Co.
11.2.1 Merck and Co. Company Information
11.2.2 Merck and Co. Overview
11.2.3 Merck and Co. Infliximab and Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Merck and Co. Infliximab and Biosimilar Products and Services
11.2.5 Merck and Co. Infliximab and Biosimilar SWOT Analysis
11.2.6 Merck and Co. Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Infliximab and Biosimilar Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Pfizer Infliximab and Biosimilar Products and Services
11.3.5 Pfizer Infliximab and Biosimilar SWOT Analysis
11.3.6 Pfizer Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Infliximab and Biosimilar Value Chain Analysis
12.2 Infliximab and Biosimilar Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Infliximab and Biosimilar Production Mode & Process
12.4 Infliximab and Biosimilar Sales and Marketing
12.4.1 Infliximab and Biosimilar Sales Channels
12.4.2 Infliximab and Biosimilar Distributors
12.5 Infliximab and Biosimilar Customers
13 Market Dynamics
13.1 Infliximab and Biosimilar Industry Trends
13.2 Infliximab and Biosimilar Market Drivers
13.3 Infliximab and Biosimilar Market Challenges
13.4 Infliximab and Biosimilar Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Infliximab and Biosimilar Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Infliximab
Table 3. Major Manufacturers of Infliximab-dyyb
Table 4. Major Manufacturers of Infliximab-abda
Table 5. Global Infliximab and Biosimilar Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Infliximab and Biosimilar Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Infliximab and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Infliximab and Biosimilar Revenue Market Share by Region (2018-2023)
Table 9. Global Infliximab and Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Infliximab and Biosimilar Revenue Market Share by Region (2024-2034)
Table 11. Global Infliximab and Biosimilar Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 12. Global Infliximab and Biosimilar Sales by Region (2018-2023) & (K Units)
Table 13. Global Infliximab and Biosimilar Sales Market Share by Region (2018-2023)
Table 14. Global Infliximab and Biosimilar Sales by Region (2024-2034) & (K Units)
Table 15. Global Infliximab and Biosimilar Sales Market Share by Region (2024-2034)
Table 16. Global Infliximab and Biosimilar Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 17. Global Infliximab and Biosimilar Sales Quantity Share by Manufacturers (2018-2023)
Table 18. Global Infliximab and Biosimilar Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Infliximab and Biosimilar Revenue Share by Manufacturers (2018-2023)
Table 20. Global Infliximab and Biosimilar Price by Manufacturers 2018-2023 (USD/Unit)
Table 21. Global Key Players of Infliximab and Biosimilar, Industry Ranking, 2021 VS 2024
Table 22. Global Infliximab and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Infliximab and Biosimilar by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Infliximab and Biosimilar as of 2024)
Table 24. Global Key Manufacturers of Infliximab and Biosimilar, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Infliximab and Biosimilar, Product Offered and Application
Table 26. Global Key Manufacturers of Infliximab and Biosimilar, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Infliximab and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 29. Global Infliximab and Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 30. Global Infliximab and Biosimilar Sales Quantity Share by Type (2018-2023)
Table 31. Global Infliximab and Biosimilar Sales Quantity Share by Type (2024-2034)
Table 32. Global Infliximab and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Infliximab and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Infliximab and Biosimilar Revenue Share by Type (2018-2023)
Table 35. Global Infliximab and Biosimilar Revenue Share by Type (2024-2034)
Table 36. Infliximab and Biosimilar Price by Type (2018-2023) & (USD/Unit)
Table 37. Global Infliximab and Biosimilar Price Forecast by Type (2024-2034) & (USD/Unit)
Table 38. Global Infliximab and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 39. Global Infliximab and Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 40. Global Infliximab and Biosimilar Sales Quantity Share by Application (2018-2023)
Table 41. Global Infliximab and Biosimilar Sales Quantity Share by Application (2024-2034)
Table 42. Global Infliximab and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Infliximab and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Infliximab and Biosimilar Revenue Share by Application (2018-2023)
Table 45. Global Infliximab and Biosimilar Revenue Share by Application (2024-2034)
Table 46. Infliximab and Biosimilar Price by Application (2018-2023) & (USD/Unit)
Table 47. Global Infliximab and Biosimilar Price Forecast by Application (2024-2034) & (USD/Unit)
Table 48. North America Infliximab and Biosimilar Revenue by Company (2018-2023) & (US$ Million)
Table 49. North America Infliximab and Biosimilar Sales Quantity by Company (2018-2023) & (K Units)
Table 50. North America Infliximab and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 51. North America Infliximab and Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 52. North America Infliximab and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 53. North America Infliximab and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Infliximab and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 55. North America Infliximab and Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 56. North America Infliximab and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 57. North America Infliximab and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Infliximab and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 59. North America Infliximab and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 60. North America Infliximab and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Infliximab and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 62. North America Infliximab and Biosimilar Sales Quantity by Country (2024-2034) & (K Units)
Table 63. Europe Infliximab and Biosimilar Sales Quantity by Company (2018-2023) & (K Units)
Table 64. Europe Infliximab and Biosimilar Revenue by Company (2018-2023) & (US$ Million)
Table 65. Europe Infliximab and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 66. Europe Infliximab and Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 67. Europe Infliximab and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 68. Europe Infliximab and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Infliximab and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Europe Infliximab and Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 71. Europe Infliximab and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 72. Europe Infliximab and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Infliximab and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 74. Europe Infliximab and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 75. Europe Infliximab and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Infliximab and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 77. Europe Infliximab and Biosimilar Sales Quantity by Country (2024-2034) & (K Units)
Table 78. China Infliximab and Biosimilar Sales Quantity by Company (2018-2023) & (K Units)
Table 79. China Infliximab and Biosimilar Revenue by Company (2018-2023) & (US$ Million)
Table 80. China Infliximab and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 81. China Infliximab and Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 82. China Infliximab and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 83. China Infliximab and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Infliximab and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 85. China Infliximab and Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 86. China Infliximab and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 87. China Infliximab and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Infliximab and Biosimilar Sales Quantity by Company (2018-2023) & (K Units)
Table 89. APAC Infliximab and Biosimilar Revenue by Company (2018-2023) & (US$ Million)
Table 90. APAC Infliximab and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 91. APAC Infliximab and Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 92. APAC Infliximab and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 93. APAC Infliximab and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Infliximab and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 95. APAC Infliximab and Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 96. APAC Infliximab and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 97. APAC Infliximab and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Infliximab and Biosimilar Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 99. APAC Infliximab and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
Table 100. APAC Infliximab and Biosimilar Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Infliximab and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 102. APAC Infliximab and Biosimilar Sales Quantity by Region (2024-2034) & (K Units)
Table 103. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Company (2018-2023) & (K Units)
Table 104. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Company (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Type (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Type (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Application (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Application (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 117. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity by Country (2024-2034) & (K Units)
Table 118. Janssen Biotech Company Information
Table 119. Janssen Biotech Description and Overview
Table 120. Janssen Biotech Infliximab and Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 121. Janssen Biotech Infliximab and Biosimilar Product and Services
Table 122. Janssen Biotech Infliximab and Biosimilar SWOT Analysis
Table 123. Janssen Biotech Recent Developments
Table 124. Merck and Co. Company Information
Table 125. Merck and Co. Description and Overview
Table 126. Merck and Co. Infliximab and Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 127. Merck and Co. Infliximab and Biosimilar Product and Services
Table 128. Merck and Co. Infliximab and Biosimilar SWOT Analysis
Table 129. Merck and Co. Recent Developments
Table 130. Pfizer Company Information
Table 131. Pfizer Description and Overview
Table 132. Pfizer Infliximab and Biosimilar Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 133. Pfizer Infliximab and Biosimilar Product and Services
Table 134. Pfizer Infliximab and Biosimilar SWOT Analysis
Table 135. Pfizer Recent Developments
Table 136. Key Raw Materials Lists
Table 137. Raw Materials Key Suppliers Lists
Table 138. Infliximab and Biosimilar Distributors List
Table 139. Infliximab and Biosimilar Customers List
Table 140. Infliximab and Biosimilar Market Trends
Table 141. Infliximab and Biosimilar Market Drivers
Table 142. Infliximab and Biosimilar Market Challenges
Table 143. Infliximab and Biosimilar Market Restraints
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Infliximab and Biosimilar Product Picture
Figure 2. Global Infliximab and Biosimilar Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Infliximab and Biosimilar Market Share by Type in 2024 & 2034
Figure 4. Infliximab Product Picture
Figure 5. Infliximab-dyyb Product Picture
Figure 6. Infliximab-abda Product Picture
Figure 7. Global Infliximab and Biosimilar Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 8. Global Infliximab and Biosimilar Market Share by Application in 2024 & 2034
Figure 9. Crohn's Disease
Figure 10. Pediatric Crohn's Disease
Figure 11. Ulcerative Colitis
Figure 12. Rheumatoid Arthritis
Figure 13. Ankylosing Spondylitis
Figure 14. Psoriatic Arthritis
Figure 15. Plaque Psoriasis
Figure 16. Infliximab and Biosimilar Report Years Considered
Figure 17. Global Infliximab and Biosimilar Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 18. Global Infliximab and Biosimilar Revenue 2018-2034 (US$ Million)
Figure 19. Global Infliximab and Biosimilar Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 20. Global Infliximab and Biosimilar Sales Quantity 2018-2034 (K Units)
Figure 21. Global Infliximab and Biosimilar Sales Quantity Market Share by Region (2018-2023)
Figure 22. Global Infliximab and Biosimilar Sales Quantity Market Share by Region (2024-2034)
Figure 23. North America Infliximab and Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. North America Infliximab and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Europe Infliximab and Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. Europe Infliximab and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 27. China Infliximab and Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. China Infliximab and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 29. APAC Infliximab and Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 30. APAC Infliximab and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity YoY (2018-2034) & (K Units)
Figure 32. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue YoY (2018-2034) & (US$ Million)
Figure 33. The Top 10 and Top 5 Players Market Share by Infliximab and Biosimilar Sales Quantity in 2024
Figure 34. The Top 10 and Top 5 Players Market Share by Infliximab and Biosimilar Revenue in 2024
Figure 35. Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 36. Global Infliximab and Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 37. Global Infliximab and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 38. Global Infliximab and Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 39. Global Infliximab and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 40. North America Infliximab and Biosimilar Revenue Market Share by Company in 2024
Figure 41. North America Infliximab and Biosimilar Sales Quantity Market Share by Company in 2024
Figure 42. North America Infliximab and Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 43. North America Infliximab and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 44. North America Infliximab and Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 45. North America Infliximab and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 46. North America Infliximab and Biosimilar Revenue Share by Country (2018-2034)
Figure 47. North America Infliximab and Biosimilar Sales Quantity Share by Country (2018-2034)
Figure 48. U.S. Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 49. Canada Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 50. Europe Infliximab and Biosimilar Sales Quantity Market Share by Company in 2024
Figure 51. Europe Infliximab and Biosimilar Revenue Market Share by Company in 2024
Figure 52. Europe Infliximab and Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 53. Europe Infliximab and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 54. Europe Infliximab and Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 55. Europe Infliximab and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 56. Europe Infliximab and Biosimilar Revenue Share by Country (2018-2034)
Figure 57. Europe Infliximab and Biosimilar Sales Quantity Share by Country (2018-2034)
Figure 58. Germany Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 59. France Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 60. U.K. Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 61. Italy Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 62. Russia Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 63. China Infliximab and Biosimilar Sales Quantity Market Share by Company in 2024
Figure 64. China Infliximab and Biosimilar Revenue Market Share by Company in 2024
Figure 65. China Infliximab and Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 66. China Infliximab and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 67. China Infliximab and Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 68. China Infliximab and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 69. APAC Infliximab and Biosimilar Sales Quantity Market Share by Company in 2024
Figure 70. APAC Infliximab and Biosimilar Revenue Market Share by Company in 2024
Figure 71. APAC Infliximab and Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 72. APAC Infliximab and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 73. APAC Infliximab and Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 74. APAC Infliximab and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 75. APAC Infliximab and Biosimilar Revenue Share by Region (2018-2034)
Figure 76. APAC Infliximab and Biosimilar Sales Quantity Share by Region (2018-2034)
Figure 77. Japan Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 78. South Korea Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 79. China Taiwan Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 81. India Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 82. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue Market Share by Company in 2024
Figure 84. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America Infliximab and Biosimilar Sales Quantity Share by Country (2018-2034)
Figure 89. Middle East, Africa and Latin America Infliximab and Biosimilar Revenue Share by Country (2018-2034)
Figure 90. Brazil Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 91. Mexico Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 92. Turkey Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 93. Israel Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 94. GCC Countries Infliximab and Biosimilar Revenue (2018-2034) & (US$ Million)
Figure 95. Infliximab and Biosimilar Value Chain
Figure 96. Infliximab and Biosimilar Production Process
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Distributors Profiles
Figure 99. Bottom-up and Top-down Approaches for This Report
Figure 100. Data Triangulation
Figure 101. Key Executives Interviewed